Houston data scientist joins medical device startup amid AI evolution in the sector

HOUSTON INNOVATORS PODCAST EPISODE 241

Angela Wilkins joins the Houston Innovators Podcast to discuss the intersection of data and health care. Photo courtesy

When most people hear about Houston startup Starling Medical, they might think about how much potential the medical device company has in the field of urinalysis diagnostics. But that's not quite where Angela Wilkins's head went.

Wilkins explains on the Houston Innovators Podcast that when she met the company's co-founders, Hannah McKenney and Drew Hendricks, she recognized them as very promising startup leaders taking action on a real health care problem. Starling's device can collect urine and run diagnostics right from a patient's toilet.

"It was one of those things where I just thought, 'They're going to get a bunch of data soon,'" Wilkins says. "The opportunity is just there, and I was really excited to come on and build their AI platform and the way they are going to look at data."

For about a year, Wilkins supported the startup as an adviser. Now, she's working more hands on as chief data officer as the company grows.



Wilkins, who serves as a mentor and adviser for several startups, has a 20-year career in Houston across all sides of the innovation equation, working first at Baylor College of Medicine before co-founding Mercury Data Science — now OmniScience. Most recently she served as executive director of the Ken Kennedy Institute at Rice University.

This variety in her resume makes her super connective — a benefit to all the startups she works with, she explains. The decision to transition to a startup team means she gets to work hands on in building a technology — while bringing in her experience from other institutions.

"I think I've really learned how to partner with those institutions," she says on the show. "I've really learned how to make those bridges, and that's a big challenge that startups face."

"When we talk about the Houston innovation ecosystem, it's something we should be doing better at because we have so many startups and so many places that would like to use better technology to solve problems," she continues.

Wilkins has data and artificial intelligence on the mind in everything she does, and she even serves on a committee at the state level to learn and provide feedback on how Texas should be regulating AI.

"At the end of the day, the mission is to put together a report and strategy on how we think Texas should think about AI," she explains. "It's beyond just using an algorithm, they need infrastructure."

Colorado is the first state to pass legislation surrounding AI, and Wilkins says all eyes are on how execution of that new law will go.

"We should have technology that can be double checked to make sure we're applying it in a way that's fair across all demographics. It's obvious that we should do that — it's just very hard," she says.

Procyrion has announced the closing of its series E round of funding. Photo via Getty Images

Houston medical device company secures $57.7M to fund journey to FDA approval, commercialization

fresh funding

Houston-born and bred medical device company, Procyrion, has completed its series E with a raise of $57.7 million, including the conversion of $10 million of interim financing.

Procyrion is the company behind Aortix, a pump designed to be placed in the descending thoracic aorta of heart failure patients, which has been shown to improve cardiac performance in seriously ill subjects. The money raised will allow the company to proceed with a the DRAIN-HF Study, a pivotal trial that will be used for eventual FDA approval and commercialization.

The Aortix is the brainchild of Houston cardiologist Reynolds Delgado. According to Procyrion’s CSO, Jace Heuring, Delgado, gained some of his experience with devices for the heart working with legendary Texas Heart Institute surgeon O.H. “Bud” Frazier. He filed his first patents related to the Aortix in 2005.

Heuring says that the first prototypes were built in 2011, followed by the final design in 2018. CEO Eric Fain, a California-based MD and with more than 30 years in the medical device industry, joined the company in 2018 ahead of the final design, primed to bring Aortix to the public. He visits the company’s Houston headquarters, across the street from Central Market, on a regular basis.

The device’s pilot study of 18 patients was completed in 2022. Those encouraging results paved the way for the current study, which will include an enrollment of 134 patients. The randomized study will seek to treat patients with acute decompensated heart failure. Half will be treated with standard-of-care therapy, the other half will be catheterized with an Aortix pump. A separate arm of the study will seek to treat end-stage heart failure patients who would otherwise be deemed too sick for either a transplant or an LVAD permanent pump. Fort-five healthcare centers in the United States will participate, including Texas Heart Institute.

“One of the key characteristics is [the patients] are retaining a lot of fluid,” explains Heuring in a video interview. “And when I say a lot, I mean it could be 25 or 30 or 40 pounds of fluid or more. When we put our pump in, one of the main goals is to reduce that fluid load.”

On average, about 11 liters of fluid came off of each patient. Many of those end-stage patients had previously been considered for both a heart and kidney transplant, but after using the Aortix, their kidneys responded so well that they were able to get only the heart transplant.

“These patients really are in dire straits and come into the hospital and today the only proven therapy to help these patients is to administer high doses of intravenous diuretic and some other cardiac drugs and in about 25 percent of patients those therapies are ineffective,” says Fain.

If Aortix gains approval, these sickest of the sick, usually consigned to hospice care, will have hope.

Thanks to the Series E, led by Houston’s Fannin Partners, returning investors, including Bluebird Ventures, the Aortix is inching closer to commercialization. Besides funding the DRAIN-HR study, Procyrion will also use the funds for internal programs to improve product manufacturability. One more step towards meaning advanced heart failure may not always be a death sentence.

Last month, Atul Varadhachary, managing director of Fannin, joined the Houston Innovators Podcast and alluded to Procyrion's raise. The company was born out of Fannin and still resides in the same building as Fannin.

Aortix is a pump designed to be placed in the descending thoracic aorta of heart failure patients. Photo via Procyrion

Houston-based EndoQuest has closed a $42 million round. Photo via Getty Images

Houston medical robotics startup announces $42M series C

cha-ching

A Houston medical device company that's tapping into robotics technology for the operating room has just announced a major chunk of fresh funding.

EndoQuest Robotics Inc. announced that it has closed a $42 million series C to advance its robot technology that's targeting endoluminal and gastrointestinal minimally invasive procedures. Returning investors, CE Ventures Limited and McNair Interests, and new investor, Puma Venture Capital, led the round of funding.

"Our investors share our vision of leveraging robotics to redefine the possibilities in minimally invasive procedures," Kurt Azarbarzin, CEO of EndoQuest Robotics, says in a press release. "This financing enables us to continue innovating and refining our technology, ultimately improving patient care and transforming the future of endoluminal interventions."

The funding will go toward continued research and development, regulatory initiatives, commercialization, and other key initiatives. Dr. Vipul Patel, the co-founder and senior venture partner of Puma Venture Capital, is a robotic urologic surgeon and sees potential in EndoQuest's technology.

"I've had the privilege of seeing just about every robotic surgical system either in development or on the market today and can honestly say that EndoQuest's system is a true game changer for both physicians and patients," Patel says in the release.

Founded in 2017, EndoQuest's robotics technology has not yet been cleared by the FDA and is not for commercial sale in the United States.

"The EndoQuest team is trailblazing novel solutions in minimally invasive surgery," Neeraj Agrawal, executive director of Crescent Enterprises, the parent organization to CE Ventures Limited. "We welcome our new partners, and remain fully supportive of the Company and the prospects to transform healthcare with our innovative endoluminal surgical platform."

EndoQuest Robotics is targeting endoluminal and gastrointestinal minimally invasive procedures. Image via endoquestrobotics.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston hardtech accelerator names 8 founders to 2026 cohort

hardtech fellows

Hardtech-focused organization Activate has named 50 new members to its 2026 cohort of scientists, which includes eight startups joining Activate Houston.

Activate aims to support scientists at "the outset of their entrepreneurial journey." It partners with U.S.-based funders and research institutions to support its fellows in developing high-impact technology. Its fellows receive a living stipend, research and development funding, connections from Activate's robust network of mentors and access to a curriculum specific to the program for two years.

This year's fellows represent 41 companies from 22 U.S. cities and 11 states.

“This cohort clearly demonstrates that the next industry-defining companies won't choose between modern technology and deep science; they'll be built by combining both,” Cyrus Wadia, CEO of Activate, said in the announcement. “These are the scientists and engineers turning our most urgent global challenges into the companies that will deliver a more sustainable future.”

The Houston fellows are working across the energy, space, AI infrastructure and agriculture sectors. They include:

  • Sophie Clare Broun, founder of Anning Corporation, which is producing clean hydrogen by stimulating naturally occurring geologic deposits
  • Kathy Andersen, founder of Brint Tech, which builds optical sensing systems that quantify hydrogen for infrastructure operators
  • Dorsa Talebi, founder of Kinetiq Drive, which builds rare-earth-free, contact-free electric motors with wireless rotors for small appliances and heavy industry alike
  • Neethu Pottackal, founder of Nivera, which is developing natural, edible coatings made from agricultural byproducts to reduce food waste and extend the shelf life of fresh food
  • Jonathan Huffman, founder of Orbital Arc, which is shrinking spacecraft propulsion to a microchip powerful enough for deep space
  • Tim Lee, founder of Renesin, which develops advanced materials for faster, more efficient AI hardware
  • Joshua Livingston, founder of Selerra Separations, which is developing high-performance membranes that cut the cost and energy consumption of water treatment
  • Wenli Jiang, founder of SwieNitro Recovery, which is developing technology that converts nitrogen-rich waste streams into valuable fertilizer

"Home to the largest concentration of engineers in the United States and a dense ecosystem of Fortune 100 and Fortune 500 companies, Houston is uniquely positioned for scientists tackling large-scale industrial challenges. Activate Houston fellows are connected to the city's deep networks in energy, chemicals, and materials," Activate said in the announcement.

Activate named its inaugural Houston cohort in 2024. It has other hubs in Boston, New York, and Berkley, California—where Activate is headquartered. The organization also offers a virtual and remote cohort, known as Activate Anywhere. Nationally, it has supported 346 fellows and 276 companies since 2015.

Activate Houston is led by managing director Jeremy Pitts, who co-founded Greentown Labs in Boston. It is based out of the Ion. The latest cohort is Activate Houston's third. Read more about the last year's cohort here.

Rice, Houston Methodist award $90K for cancer research projects

seed grants

Rice University’s Synthesis X Center, in partnership with the Houston Methodist Neal Cancer Center, announced earlier this month the organizations would award $90,000 in seed grant funding to two projects that could help fight cancer. One would ease the pain of chemotherapy, while the other could change the way the progression of leukemia is tracked.

“We’re excited to be collaborating with the Neal Cancer Center to support collaborative, novel and interdisciplinary proposals to improve cancer care and outcomes,” Han Xiao, Rice professor of chemistry and the director of the SynthX Center, said in a news release. “Together, we can achieve translational excellence.”

The projects

Chemotherapy is one of the most effective cancer treatments, but it can be hard on the body. The human body doesn’t like being injected with radioactive material, especially the skin around the injection point, which can become extremely irritated. For patients in long-term treatment, the skin irritation can be more than just a bother; it can lead to infections that are dangerous to a compromised immune system.

Angel A Marti, a professor of chemistry at Rice University, and Biana Godin, an associate professor of nanoscience at Houston Methodist Research Institute, are experimenting with metal nanoclusters as a way to block radiation at the injection site. The nanocluster could be applied in a cream or a gel on the skin, serving as a type of shield against the harsh radioactive material.

Meanwhile, Yuan Ma, an assistant professor of chemistry at Rice, and Shu-Hsia Chen, a professor of immunology at Houston Methodist Research Institute, are working with m6A. Discovered in the 1970s, m6A is the most prevalent chemical modifier found in mRNA in mammals. It is prevalent in many cancers, including leukemia.

Ma and Chen are working on measuring the amount of m6A in leukemia to see if it can determine the most effective cancer treatments. The team is also experimenting with ways to shut off m6A to see if it makes current leukemia treatments more effective.

Progress from SynthX

SynthX was first launched in April 2024 to turn research from Rice and Houston Methodist into real-world cancer treatments. Within a year, the center had secured $1.5 million in grant money to work on crossing the blood-brain barrier in brain cancer treatments. These latest awards show that SynthX Center continues to bridge the worlds of research and clinical practice.

“This collaboration reflects a shared commitment to team science in cancer research,” Daniela Matei, the director of the Houston Methodist Neal Cancer Center, added in the release. “These are the types of translational and pioneering projects that lead to transformation in patient care.”'

The SynthX Center awarded $90,000 in seed grants to three teams in 2025 and $80,000 to three teams in 2024.

Tesla self-driving mode wasn't to blame in Houston-area crash, report suggests

Tesla news

Federal safety investigators looking into a runaway Tesla that killed a grandmother in her home say the driver had pressed the accelerator to full speed, suggesting the vehicle's self-driving software was not to blame.

The driver had told police that he had the self-driving software turned on, but a report from the National Transportation Safety Board concluded that he had actually overridden that feature when he pushed hard on the pedal. Moments later the Tesla Model 3 raced down a residential street in Katy, Texas, at highway speeds, slammed into a brick home and killed a 76-year-old woman standing in the front room.

The crash last month drew national attention because Tesla CEO Elon Musk is seeking to reassure the public its self-driving feature is safe as he prepares to turn hundreds of thousands of Teslas already on the road into fully automatic vehicles and begin selling two-seated Cybercabs missing steering wheels and pedals.

The crash came two months after officials at a separate federal agency, the National Highway Traffic Safety Administration, announced it was elevating a 2024 investigation of the self-driving feature to new “engineering analysis” level, raising the possibility of a recall of 3.2 million Tesla vehicles.

That NHTSA probe was triggered by crashes where the self-driving feature failed to alert drivers to take control in fog and other poor visibility conditions.

The agency opened an investigation last year into 58 incidents in which Teslas reportedly violated traffic safety laws while using self-driving technology, leading to more than a dozen crashes and fires and nearly two dozen injuries.

Separate from the National Transportation Safety Board, NHTSA is also looking into the Tesla house crash in Texas, one of 46 “special crash” investigations of Tesla's self-driving or driver-assistance technology in the past decade, according to the agency’s records. In more than a dozen of those crashes, at least one person — a driver, passenger or pedestrian — was killed.

Tesla had originally called its driver assistance software Full Self-Driving, or FSD, but auto experts and regulators complained it was misleading because drivers must always keep their eyes on the road and be ready to take over at any time.

The company has since changed the name to Full Self-Driving (Supervised).

Video of the Katy, Texas, accident shows the Tesla traveling at more than 70 mph (112.65 kilometers per hour), jumping a curb then tearing across a lawn before crushing through a brick wall of a home. A woman standing feet away, Martha Avila, was found amid piles of crumbling plaster, split beams and bits of furniture and rushed to a hospital but died.

Sales of Tesla cars still haven't recovered fully from boycotts last year over Musk's political stands, but the stock is rising anyway as he has successfully shifted attention away from the sales figures. He says they matter less now that the company is on the cusp of major technological advances, such as turning Teslas into hands-free vehicles and having its Optimus robots take over for humans for tasks at home and work.

Tesla stock has risen 22% in the past year and is currently trading at 170 times expected annual earnings compared to 20 for the S&P 500.

For its second-quarter financial results, financial analysts surveyed by FactSet expect earnings per share will barely budge — 32 cents versus 33 cents a year earlier — continuing a sixth quarter streak of flat or falling profits.

View All Listings